Healthcare Industry News: HSMN NewsFeed
News Release - December 14, 2017
Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen SystemSAN DIEGO, Dec. 14, 2017 -- (Healthcare Sales & Marketing Network) -- Companion Medical, a leader in the development of advanced technology to improve diabetes care, announced today that it has begun commercial sales of the InPen® system in the United States. InPen is available by prescription only and is a covered benefit under many insurance plans. The InPen is for use with U-100 Lilly Humalog® and Novo Nordisk Novolog® rapid-acting insulin and indicated for persons aged 12 years and older.
"I am pleased to announce the commercial launch of InPen. The InPen system is a significant step toward true integrated diabetes management," said CEO Sean Saint. "Our team has worked diligently to develop a solution for people living with diabetes who want the benefits of an insulin pump without the cost or burden of being tethered to a device."
InPen is the first and only FDA-cleared solution that combines an insulin injector pen with an intuitive smartphone app and bolus advisor using Bluetooth® technology. InPen tracks insulin doses, including priming, and automatically sends the data to the user's mobile device, providing decision support for the constant monitoring and calculating necessary for successful insulin therapy. InPen includes technology to:
- Calculate and recommend optimal dosing;
- Track history and timing of doses for a full year;
- Monitor insulin temperature;
- Remind the user when to take insulin;
- Display last dose and insulin-on-board; and
- Generate actionable reports for the healthcare provider.
For more information, visit www.companionmedical.com.
About Companion Medical
Companion Medical, Inc. (www.companionmedical.com) is a privately held company based in San Diego, CA. The company leverages cross-functional engineering expertise, clinical experience, and first-hand knowledge of diabetes lifestyles to develop innovative solutions for diabetes management.
Source: Companion Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.